Filter Results:
(621)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
- April 2024 (Revised November 2024)
- Case
Moderna: Pioneering a People Platform to Accelerate Science Innovation
By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Biotechnology Industry; Biotechnology Industry; United States
Sandino, Tatiana, Emil Dy, and Samuel Grad. "Moderna: Pioneering a People Platform to Accelerate Science Innovation." Harvard Business School Case 124-091, April 2024. (Revised November 2024.)
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
- Spring 2014
- Article
Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company
By: Andrew Knauer and George Serafeim
Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Biotechnology Industry; Biotechnology Industry
Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.
- 01 May 2009
- Conference Presentation
The enabling and constraining effects of attention structures on entrepreneurial activity in the U.S. biodiesel industry
By: Shon R. Hiatt
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Biotechnology Industry; Biotechnology Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- July 2009
- Teaching Note
Khosla Ventures: Biofuels Strategy (TN)
Teaching Note for [809004]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Biotechnology Industry; Biotechnology Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Biotechnology Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns. Their research was conducted before... View Details
Keywords: by Sean Silverthorne
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- Aug 2011 - 2011
- Conference Presentation
Institutional Heterogeneity, Innovation, and Entrepreneurship in the U.S. Biodiesel Fuel Sector
By: Shon R. Hiatt
- 2011
- Other Unpublished Work
From Farms to Fuel Tanks: Collective Actors and New-Venture Innovation in the U.S. Biodiesel Fuel Sector
By: Shon R. Hiatt
Little is known about the influence of collective actors on innovative technological recombinations by new ventures. Using data from U.S. biodiesel producers, I examine how the efforts of multiple collective actors (farm associations) to promote varying types of... View Details
- Profile
Terrance McGuire
and entrepreneur, during which time they have collaborated on a long list of successful biotechnology startups. “Bob Langer is passionate about improving peoples' lives,” McGuire said. “He was one of the early... View Details
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne